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The combination of psoralens with UVA is used as PUVA therapy for psoriasis and other skin diseases. UVA-
induced psoralen/DNA photoadducts act via suppression of DNA replication and cell proliferation, but do not
sufﬁciently repress gene transcription. To explore whether PUVA may also be used for gene repression, psoralen
was conjugated to a triplex-forming oligonucleotide (TFO) that targets a gene sequence of ICAM-1, a key molecule
in cutaneous inﬂammation. Triplex formation between TFO and target sequence was detected by non-denaturing
gel electrophoresis. UVA-irradiation induced psoralen cross-links at the triplex–duplex junction as veriﬁed by
denaturing gel electrophoresis. When the target sequence was placed within the transcribed portion of the
chloramphenicol acetyltransferase (CAT) gene, TFO inhibited CAT expression in A431 cells. Inhibition was
sequence-speciﬁc, since a scrambled control oligonucleotide or mismatched or scrambled target sequences failed
to inhibit CAT expression. Inhibition was not signiﬁcant without UVA exposure, but was strongly enhanced by
PUVA-mediated cross-links at the TFO target site. These results suggest that TFO may add a new quality to PUVA
therapy by transcriptionally repressing pathogenically relevant genes, in addition to antiproliferative PUVA effects.
TFO designed to repress only after PUVA activation may allow the development of a cutaneous organ speciﬁc
strategy for gene repression.
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The specific knockout of a cellular target structure is an
important pharmacologic concept. Conventional drugs or
monoclonal antibodies are designed to interact at the
protein level, e.g., to modulate the function of a targeted
enzyme or receptor. An additional approach is to modulate
cell function at an earlier stage by interference with gene
expression. Several inhibitory strategies have been estab-
lished that interfere with specific target RNAs. Among them
are antisense oligonucleotides, ribozymes, and small inter-
fering RNAs (Lebedeva and Stein, 2001; Hannon, 2002;
Sullenger and Gilboa, 2002; Dykxhoorn et al, 2003). These
technologies all act at a post-transcriptional level. Alter-
natively, gene expression may be modulated at an earlier
stage, at the level of transcription, by molecules that
specifically bind to the DNA double helix, a strategy referred
to as anti-gene strategy (Giovannangeli and Helene, 2000).
As representatives of this class of molecules, triplex-
forming oligonucleotides (TFO) bind in the major groove of
the double helix via Hoogsteen hydrogen bonds, which are
formed between bases of the TFO and bases in the double
helix that are already engaged in Watson–Crick pairing.
Triplex formation via Hoogsteen interactions requires a
stretch of pyrimidines on one DNA strand and complemen-
tary purines on the other DNA strand (oligopyrimidine . oli-
gopurine sequences). Depending on their base composi-
tion, TFO bind in a parallel or antiparallel orientation to the
purine-containing strand (Thuong and He´le`ne, 1993; Faria
and Giovannangeli, 2001).
Triplex-mediated inhibition of transcription may be
achieved by interfering with transcription initiation (competi-
tion of TFO with transcription factors at the promoter) or
by interfering with transcription elongation (RNA synthesis
arrest at triplex structures). Transcription inhibition has been
described for plasmid-harbored genes (Bailey and Weeks,
2000; Faria et al, 2001), for foreign sequences in the cellular
genome (Faria et al, 2000), and in several endogenous genes
including the oncogenes c-myc (McGuffie et al, 2000), ets2
(Carbone et al, 2003), or bcr/abl (Rapozzi et al, 2002), the
inflammatory mediators TNF-a (Aggarwal et al, 1996), MCP-
1 (Marchand et al, 2000), or GM/CSF (Kochetkova et al,
1997), and the cell adhesion molecule ICAM-1 (Besch et al,
2002). In addition to the inhibition of transcription, the
possibility to form specific and stable complexes at selected
genomic sites might induce drastic cellular responses such
as modifications of cell cycle checkpoints, especially in
malignant cells (Takebayashi et al, 2001).
In order to improve the therapeutic potential of TFO,
attempts were made to optimize binding affinity, cellular
uptake, or in vivo stability, e.g., by introducing chemical
modifications of bases or oligonucleotide backbone or by
Abbreviations: CAT, chloramphenicol acetyltransferase; TFO, triplex-
forming oligonucleotide
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adding functional groups (Vasquez and Glazer, 2002). One
technique is the conjugation of TFO with psoralens
(Takasugi et al, 1991).
Psoralens are natural or synthetic furocoumarins that
randomly intercalate cellular DNA. UVA induces covalent
psoralen/DNA photoadducts in oxygen-independent photo-
chemical reactions. The psoralen molecule will first gen-
erate a photoadduct with one strand of the DNA double
helix (monoadduct) and may, subsequently, form another
photoadduct on the second DNA strand, thereby cross-
linking the double helix (Gasparro et al, 1997). The
combination of unconjugated psoralen and UVA is a widely
used dermatologic treatment for psoriasis and other
inflammatory as well as malignant diseases (Ho¨nigsmann
et al, 2003).
Psoralen modification of TFO may have therapeutically
relevant implications in dermatology. (i) Under therapeutic
circumstances, only a few psoralen cross-links per cell are
generated. This is sufficient to interfere with cell replication
and proliferation, but gene transcription will not be affected
due to the low likelihood that randomly located cross-links
hit a particular gene within the genome. But psoralens
conjugated to a triple helix oligonucleotide could be
directed to a specific target sequence and, thereby, allow
for a PUVA-mediated specific gene repression, e.g., of
proinflammatory genes. (ii) The combination of PUVA with
triple helix technology also has the potential to minimize the
photocarcinogenic effects of conventional PUVA: directing
psoralen photoadducts to genomic areas not involved in
gene transcription or gene regulation could decrease the
likelihood of PUVA mutations promoting cancer, whereas
maintaining antiproliferative PUVA effects. (iii) UVA irradia-
tion does not reach inner organs and, therefore, activates
psoralen-conjugated TFO only in the skin. Thus, an organ-
selective gene inhibition treatment regimen for the skin may
be established.
In this article, we present a novel psoralen-conjugated
TFO that specifically binds to its target sequence and
inhibits gene expression. Whereas a previously described
TFO (Besch et al, 2002) inhibited gene expression indepen-
dent of UVA, i.e., UVA irradiation did not further increase
gene repression, the TFO described here does not
significantly inhibit gene expression without UVA, but
unfolds inhibitory action after UVA-mediated generation of
psoralen-DNA photoadducts. The results suggest that TFO-
modified PUVA may repress pathogenically relevant genes
adding a new therapeutic quality to PUVA in addition to
antiproliferative effects. Furthermore, TFO that are active
only after PUVA may be used to develop a cutaneous organ
specific gene repression strategy.
Results
Design of a TFO The ICAM-1 gene sequence was
screened for suitable targets for triplex formation. A 16 bp
oligopyrimidine . oligopurine sequence was selected that is
located in the 30 untranslated region of exon seven (Fig 1).
Adjacent to the target sequence, there is a 50-TpA motif
suitable for psoralen/UVA-induced photoadduct generation.
The oligonucleotide TFO was designed to form a triple helix
at this site. TFO contains guanosine and thymidine nucleo-
sides allowing the formation of T. A  T and C . G  G base
triplets (with [ . ] standing for Watson–Crick interactions and
[  ] for reverse Hoogsteen interactions) after binding in an
antiparallel orientation with respect to the purine strand of
the double helical target sequence. Psoralen was conju-
gated to the 50-end of TFO via an additional guanosine
nucleoside and a C6-spacer bridge to ensure appropriate
intercalation after triplex formation. The control oligodeox-
ynucleotide (CO) was designed for the demonstration of
sequence specificity of TFO binding (Fig 1). CO has a
scrambled sequence, with an identical base composition
and also containing G-runs.
TFO forms a triple helix at its target sequence and
allows for site-speciﬁc PUVA-mediated cross-links The
ability of TFO to form a triple helix with its target sequence
was tested in mobility shift assays. A 32 bp ICAM-1 DNA
fragment containing the target sequence (as depicted in Fig
1) was incubated with various concentrations of TFO or CO
and samples were subjected to non-denaturing polyacryla-
mide gel electrophoresis. When the target sequence was
incubated with TFO, a shifted species was observed, whose
intensity increased with increasing TFO concentrations (Fig
2A). No band shift was observed with CO even at high
concentrations nor with a second scrambled oligonucleo-
tide (data not shown). This is consistent with a triplex
formation at the target sequence in a sequence-specific
manner.
Figure1
Triple helix target sequence and oligonucleotides. (A) The ICAM-1
gene structure is indicated with numbered exons. A 16 bp target site is
localized in the seventh exon and corresponds to positions #2465–
#2450 of Genbank accession number NM_000201. (B) A 32 bp
gene segment is depicted, which includes the 16 bp oligopyrimidi-
ne . oligopurine target sequence (underlined) and a 50-TpA site (boxed)
suitable for psoralen/UVA photoadduct formation. Sequences of the
triplex-forming oligonucleotide (TFO) and the scrambled control
oligonucleotide (CO) are juxtaposed to the target sequence. Oligonu-
cleotides are psoralen and triethyleneglycol (TEG) conjugated as
indicated.
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We next tested whether TFO, after having bound to its
target sequence, induces cross-links to the target duplex
via its psoralen moiety and UVA exposure. The 32 bp target
fragment was incubated with TFO to allow triplex formation,
samples were UVA irradiated, and subjected to denaturing
gel electrophoresis. Photoadducts were detected as shifted
species. The amount of the lower shifted band (species b in
Fig 2B) peaked at an irradiation dose of 0.5 J per cm2,
whereas the amount of the upper shifted band (species c in
Fig 2B) steadily increased with increasing UVA doses. These
results are consistent with the formation of: (i) monoadducts
(TFO covalently linked to one strand of the double helix;
species b in Fig 2B) and (ii) cross-links (TFO linked to both
strands of the double helix; species c in Fig 2B). No band
shifts were observed if UVA was omitted, indicating that
photoadduct formation via UVA and psoralen was neces-
sary for the generation of stable covalent TFO-target
sequence complexes (Fig 2B). If TFO was replaced with
CO, there was also no band shift after irradiation, suggest-
ing that sequence-specific triplex formation is necessary for
effective photoadduct formation.
Collectively, the data demonstrate the ability of TFO to
form a triple helix at its target sequence in a sequence-
specific manner and that the triple helix provides the basis
for site-directed, PUVA-induced cross-links in the double-
stranded target sequence.
TFO inhibition of reporter gene expression is signiﬁ-
cantly enhanced by PUVA-induced DNA cross-links at
the target site We next wanted to test the functional
significance of triplex-directed, PUVA-induced cross-links
with respect to the inhibition of gene transcription. An
experimental model was established in which the plasmid
pCM52 contains the TFO target sequence positioned
between the SV40 promoter and the CAT reporter gene.
The target site is located downstream of the transcription
start site and, therefore, TFO binding to the target sequence
may interfere with CAT transcription by blocking transcrip-
tion elongation (Fig 3). When pCM52 was incubated with
TFO and subsequently transfected into A431 cells, CAT
Figure 2
Triplex formation at the target sequence. (A) A digoxigenin-labeled
() 32 bp double-stranded target fragment (5 nM) containing the ICAM-
1-target sequence (as shown in Fig 1) was incubated with various
concentrations of triplex-forming oligonucleotide (TFO) or control
oligonucleotide (CO), as indicated (see Materials and Methods for
details). Triple helices (a) were retarded under non-denaturing condi-
tions relative to unbound double-stranded target sequences (b). (B) The
digoxigenin-labeled 32 bp double-stranded target fragment (5 nM) was
incubated with oligonucleotides (5 mM) and irradiated with various UVA
dosages, as indicated. Photoadducts (c, cross-links; b, monoadducts)
were retarded under denaturing conditions relative to unbound single-
stranded target sequence (a).
Figure3
Expression plasmids containing different target sequences. The
expression plasmid pCM51 was constructed as described under
Materials and Methods and contains a multiple cloning site between
the SV40 promoter and the chloramphenicol acetyltransferase (CAT)
gene (A, ‘no target sequence’). Different sequences were cloned into
the multiple cloning site: plasmid pCM52 (B) contains the 16 bp triple
helix target sequence (underlined); pCM52m (C) contains the target
sequence in which one central base position is mutated (boxed); and
pCM53 (D) contains a 16 bp scrambled polypurine sequence (under-
lined).
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expression was slightly, but not significantly, inhibited when
compared with cells transfected with pCM52 and CO
(Fig 4). If reactions containing pCM52 and TFO were UVA
irradiated prior to transfection, CAT inhibition was signifi-
cantly enhanced compared with unirradiated reactions (Fig
4), probably due to PUVA-induced cross-links as character-
ized (Fig 2B). In contrast, if CO was present instead of TFO,
UVA did not affect CAT expression, suggesting that
sequence-specific triplex formation is a prerequisite for
effective photoadduct formation. These data suggest that
triple helix-dependent inhibition of CAT expression was
significantly enhanced by PUVA-induced DNA cross-links at
the target sequence.
Inhibition of gene expression depends on the presence
of a speciﬁc triple helix target sequence To further
demonstrate the specificity of the interaction of the TFO
with its target sequence, the TFO-mediated CAT inhibition
was assessed with several variations of the target site. To
this end, plasmids were utilized that contain the correct
target sequence (pCM52, Fig 3B), a target sequence with
one mismatch (pCM52m, Fig 3C), a scrambled sequence
(pCM53, Fig 3D), or no target sequence at all (pCM51, Fig
3A). The different plasmids were exposed to TFO, UVA-
irradiated, and transfected into A431 cells. CAT expression
under these conditions was normalized to CAT expression
of otherwise identical reactions, in which TFO was replaced
with CO. When the plasmid pCM52 containing the correct
target sequence was exposed to TFO, a marked reduction
in CAT expression, compared with exposure to CO, was
noted (Fig 5). No reduction of CAT expression by TFO
relative to CO, however, was observed when plasmids were
used with either no target sequence, a scrambled sequence,
or a mismatch target sequence differing from the correct
target at only one position. These data demonstrate the
stringent requirement for the correct target sequence and
also discourage the relevance of triple helix-independent
effects of TFO for the observed transcription inhibition.
Discussion
This study describes effective binding of a TFO to its target
sequence derived from the human ICAM-1 gene (Degitz
et al, 1991). Sequence-specific binding was demonstrated
in mobility shift assays, and transcription of a reporter gene
was effectively inhibited by TFO, when the target sequence
was part of the transcribed region of the reporter gene.
Importantly, the inhibitory effect was markedly increased by
the introduction of psoralen-UVA cross-links at the TFO
binding site.
Our data suggest that the inhibition of CATexpression was
caused by TFO binding to its double-stranded target
sequence resulting in triplex formation and inhibition of
transcription elongation. Two lines of experimental evidence
support the sequence speciﬁcity of this effect. (i) A scrambled
CO used instead of TFO failed to inhibit CAT expression
(Fig 4). (ii) The TFO-mediated inhibition was abrogated by
variations of the double-stranded target sequence (Fig 5). In
addition to triplex formation, other potential effects of TFO on
Figure 4
Triple helix-mediated inhibition of chloramphenicol acetyltransfer-
ase (CAT) expression is enhanced by psoralen/UVA. The plasmid
pCM52 containing the 16 bp triple helix target sequence was incubated
with psoralen-modified triplex-forming (TFO) or control (CO) oligonu-
cleotides and either UVA irradiated (5 J per cm2) or not. The reactions
were then used to transfect A431 cells, which were lyzed 6 h after
transfection. The amount of CAT protein was determined in lysates by
ELISA. Bars represent the percentage of CAT expression (mean  SD)
relative to CAT expression of control cells transfected with reactions
containing the plasmid, but no oligonucleotides. Statistical analysis
was performed with ANOVA (Fisher’s protected least significant
difference test).
Figure5
Triple helix formation at the target site is sequence specific.
Plasmids containing the triple helix target sequence (pCM52), no target
sequence (pCM51), a scrambled control sequence (pCM53), or a
mismatched target sequence (pCM52m) were incubated with triplex-
forming (TFO) or control (CO) oligonucleotides, and irradiated with UVA
(2 J per cm2). The reactions were then used to transfect A431 cells.
Cells were lyzed 6 h after transfection, and chloramphenicol acetyl-
transferase (CAT) protein determined in lysates by ELISA. Bars
(mean  SD of three independent experiments) represent the percen-
tage of CAT expression of cells transfected with TFO-treated plasmids
relative to cells transfected with CO-treated plasmids.
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transcription have to be considered. As one such mechan-
ism, the inhibition may be caused by post-transcriptional
inhibition of gene expression, i.e., by sequence-specific
binding of TFO to the CAT mRNA resulting in duplex
formation (antisense effect). This, however, appears unlikely,
because we did not identify a sequence in the CAT mRNA
that would support the formation of a stable duplex with
TFO or even a portion of it. As yet another possibility,
inhibition could also be due to interactions of TFO with
intracellular proteins. Oligonucleotides can bind to proteins
in a sequence-specific manner, thereby generating bio-
logic activities independent of triplex formation (Michelotti
et al, 1995; Feigon et al, 1996; Famulok and Jenne, 1998).
Variations of oligonucleotide sequence do not allow to
distinguish effects caused by sequence-specific oligonucle-
otide–protein interactions from effects caused by sequence-
specific triplex formation. Variations of the double-stranded
target sequence, however, do allow this distinction, because
they will only influence triplex formation, but not oligonucleo-
tide/protein interactions. Since in our experiments variations
of the double-stranded target sequence abrogated all
inhibitory activity of TFO (Fig 5), it can be assumed that the
observed effect was solely due to TFO binding to the correct
target sequence and that sequence-specific oligonucleo-
tide–protein interactions can be excluded. Taken together,
the data suggest that TFO inhibits reporter gene expression
by a triplex-mediated blockage of transcription elongation.
Similar observations regarding the specificity of both the TFO
and the target sequence have been made previously for
triplex-mediated transcription inhibition (Faria et al, 2000;
Carbone et al, 2003) or other experimental systems, e.g.
triplex-induced mutagenesis or recombination (Barre et al,
2000; Luo et al, 2000).
We have utilized UVA-activation of psoralens conjugated
to the TFO in order to introduce DNA cross-links. The
combination of unconjugated psoralens with UVA has been
used as PUVA therapy for more than 30 y to treat psoriasis
and several other inflammatory and malignant skin diseases
(Ho¨nigsmann et al, 2003). It is assumed that UVA-induced
photoadducts of psoralens to DNA suppress replication and
cell proliferation. Thereby, PUVA antagonizes hyperproli-
ferative states of epidermal keratinocytes, e.g., in psoriasis,
and also interferes with the expansion of skin infiltrating
T lymphocytes that sustain inflammation. PUVA may even
induce leukocyte apoptosis, which may contribute con-
siderably to anti-inflammatory effects in psoriasis or to
the decrease of skin infiltrating tumor cells in cutaneous
T cell lymphomas (Johnson et al, 1996; Yoo et al, 1996).
Unconjugated psoralens randomly intercalate cellular DNA.
At therapeutical concentrations, only a few psoralen
photoadducts per million base pairs are expected (Tokura
et al, 1991). This may already significantly impede cell
division, because a single psoralen cross-link within the
human genome can theoretically interfere with replication.
In contrast, the likelihood for PUVA photoadducts to inter-
fere with the transcription of a particular gene is low, since a
psoralen photoadduct needs to be generated within the
short stretch of a few kilobases representing the transcrip-
tional unit of a particular gene. Accordingly, inhibition of
gene expression is not observed under therapeutical PUVA
conditions (Lu¨ftl et al, 1998).
Although there is a lack of interference with gene
transcription by unconjugated psoralens used in conven-
tional PUVA, this can be overcome by conjugating psoralens
to TFO, which allow to direct psoralen exactly to a particular
DNA location, at which cross-links can be generated via
UVA. As demonstrated in this study, triplex-mediated
direction of psoralen cross-links to the transcribed region
of a reporter gene effectively inhibited gene expression.
Hence, triple helix technology may be used to modify PUVA
therapy so as to inhibit specifically genes of interest in
addition to antiproliferative PUVA effects. The inhibitory
activity of psoralen-conjugated TFO has been observed
with other plasmid-based systems both with regard to
inhibition of transcription elongation (Degols et al, 1994;
Macaulay et al, 1995; Musso et al, 1996; Intody et al, 2000)
and transcription initiation (Grigoriev et al, 1993).
From a different perspective, triple helix technology
could minimize the photocarcinogenic effects of conven-
tional PUVA therapy: directing photoadducts to genomic
areas that are not involved in gene transcription or gene
regulation could decrease the likelihood of PUVA-induced
mutations that promote cancer, but still inhibit cell prolifera-
tion. The systemic or cutaneous delivery of TFO seems
possible inasmuch as advances of antisense technology for
an effective systemic (Akhtar et al, 2000) or cutaneous
(Brand and Iversen, 2000) delivery may be utilized.
Triplex structures consisting of TFO and its target
sequence in the reporter plasmid were formed prior to
transfection into the cell. Non-covalent triplex structures
could have been destroyed, e.g., during incorporation into
the transfection adjuvant or because of suboptimal magne-
sium concentrations after dilution in transfection medium,
prior to entering the cell. But several arguments support the
view that the non-covalent triplexes were intactly delivered
into cells: (i) preformed triplex structures remained intact
when incorporated in cationic liposomes (Sedelnikova et al,
1999). (ii) Triplex structures preformed at standard magne-
sium concentration (10 mM MgCl2) do not dissociate when
the magnesium concentration is lowered by dilution to 1
mM (Sedelnikova et al, 1999; Whitehouse et al, 2003), a
magnesium concentration similar to the one present in our
transfection medium.
The amount of triplex-mediated cross-links was a
function of the UVA dose (Fig 2B), and increasing amounts
of cross-links have been observed with increasing UVA
dosages in previous studies (Macaulay et al, 1995; Besch et
al, 2002). The observed UVA-associated inhibition of CAT
expression was not due to psoralen/UVA-associated
cellular phototoxic effects (Lu¨ftl et al, 1998; Ho¨nigsmann
et al, 2003), because UVA irradiation was performed prior to
transfection into cells.
The TFO used in this study required UVA exposure for
efficient inhibitory activity, suggesting that UVA-induced
psoralen/DNA cross-links were important for the observed
biologic effect. Of note, formal controls to demonstrate the
necessity of UVA irradiation as installed in this study (Fig 4)
have been only rarely described previously (Grigoriev et al,
1993; Intody et al, 2000). This UVA dependence is not
generally observed. Some TFO were reported that dis-
played a marked inhibitory effect without psoralen/UVA or
other modifications (Faria et al, 2000; Besch et al, 2002).
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The differential biologic behavior of TFO in these reports as
compared with our findings could be related to differences
in oligonucleotide binding strength to targets under cellular
conditions. But a direct comparison of the studies is difficult
because of different experimental settings, including trans-
fection conditions and irradiation dosages. At any rate, our
findings and the aforementioned studies are consistent with
the assumption that some TFO, due to their comparatively
strong binding affinities, exert their biologic effect so effi-
ciently that no further enhancement by psoralen/UVA
interactions is achieved, whereas other TFO, due to their
comparatively low binding affinities, do not sufficiently
inhibit gene expression by themselves, but benefit from
psoralen/UVA interactions.
Whereas, in principle, a high binding affinity is desirable,
in particular situations, a low binding activity that can be
increased and stabilized by psoralen/UVA could be suitable,
especially with regard to the development of a skin-specific
therapeutic system. UVA penetrates the upper layers of the
skin (Kochevar and Taylor, 2003), but does not reach inner
organs and, therefore, would selectively activate psoralen-
conjugated TFO in the skin, but not in deeper organs, after
systemic application. This could lead to less or no extra-
cutaneous biologic effects, or side effects.
Materials and Methods
Oligodeoxynucleotides The sequences of the TFO and of the CO
are displayed in Fig 1. Unmodified and digoxigenin-modified
phosphodiester oligodeoxynucleotides were obtained from Meta-
bion (Mu¨nchen, Germany). Psoralen-modified phosphodiester
oligodeoxynucleotides were purchased from Qbiogene (Heidel-
berg, Germany). 50-ends were modified with 4,50,8-trimethylpsor-
alen via a six carbon linker. Ends that were not modified with a
psoralen moiety were conjugated to a triethyleneglycol group to
prevent nuclease-mediated degradation.
UVA treatment UVA was applied with a PUVA 200 light arch
(Waldmann, Villingen-Schwenningen, Germany) with F8T5 PUVA
bulbs, whose emission spectrum is mainly between 315 and 365
nm. Irradiation was carried out at room temperature through
window glass in order to eliminate traces of UVB. The irradiation
dose delivered to the samples was determined by a UV meter
(Waldmann) and the fluence was 2 mW per cm2 at a 19 cm source
to target distance.
Mobility shift assays Triple helix formation was analyzed in
mobility shift assays. A 32 bp double-stranded DNA fragment
representing the ICAM-1 target locus and containing the 16 bp
oligopyrimidine . oligopurine sequence (Fig 1) was produced by
annealing equimolar amounts of complementary single-stranded
oligodeoxynucleotides, which had been labeled with digoxigenin at
the 50-ends (Metabion). The double-stranded target DNA (50 fmol)
was incubated with various concentrations of TFO or CO in 10 mL
of a triplex-forming buffer (10 mM Tris-HCl, pH 7.5; 10 mM MgCl2;
1 mM spermidine). After incubation for 90 min at 371C, triple
helices were assessed in mobility shift assays by subjecting
samples to a non-denaturing gel electrophoresis (16% polyacry-
lamide gel containing 50 mM Hepes, pH 7.5; 10 mM MgCl2; 1 mM
spermidine; migration at 371C).
In order to assess triple helix-induced psoralen/UVA cross-links,
the digoxigenin-labeled double-stranded target DNA (5 nM) was
incubated with 5 mM of either triplex forming or CO in triplex-
forming buffer. Reactions were then irradiated with various UVA
doses. Psoralen/UVA-induced covalent photoadducts between the
double-stranded target and TFO were assessed by denaturing gel
electrophoresis (16% polyacrylamide gel containing 7 M urea; 10%
glycerine in 44.5 mM Tris; 44.5 mM boric acid; 1 mM EDTA, pH 8.3).
Under these conditions, non-covalent triple helices are destroyed,
whereas covalent photoadducts persist and result in band shifts.
Cell culture The human squamous cell carcinoma-derived cell
line A431 was from American Type Culture Collection (Manassas,
Virginia). Cells were cultured in Dulbecco’s modified Eagle medium
supplemented with 2 mM L-glutamine, 100 U per mL penicillin, 100
mg per mL streptomycin, 1 mg per mL amphotericin B (all from Life
Technologies, Karlsruhe, Germany), and 10% heat-inactivated fetal
calf serum (ccpro, Neustadt, Germany), at 371C and 5% CO2. Cells
were used for experiments at subconfluency and kept in serum-
free medium during experiments.
Construction of expression vectors The plasmid pCM51 was
constructed from the vectors pSV-b Gal and pCAT-Basic (Prome-
ga, Mannheim, Germany). In this plasmid, the chloramphenicol
acetyltransferase (CAT) reporter gene is expressed under control of
the SV40 promoter (Fig 3). A multiple cloning site between the
SV40 promoter and the CAT gene was used to incorporate short
DNA sequences representing triple helix target sites that, if bound
by a TFO, should interfere with CAT transcription elongation. The
incorporated DNA sequences were constructed by annealing
complementary oligonucleotides, and their correct insertion as
single copies was controlled by sequencing (ABI PRISM, Perkin-
Elmer, U¨berlingen, Germany).
Transient transfection of cells Prior to transfection into A431
cells, plasmids (0.5 pmol) and TFO (500 pmol) were incubated in 10
mL triplex-forming buffer for 90 min at 371C. UVA irradiation was
performed to allow photoadduct formation. The reaction was then
diluted with Dulbecco’s modified Eagle medium containing 10%
fetal calf serum without antibiotics/antimycotics to a volume of 65
mL and mixed with 7.5 mL of Superfect (cationic activated
dendrimer, Qiagen Hilden, Germany) to form DNA/dendrimer
complexes. After a 10-min incubation at room temperature, the
transfection mixture was further diluted with medium to a volume
of 800 mL (to a 0.6 mM final concentration of plasmid in the culture
medium), and added to subconfluent cells in a six-well culture
plate (3 cm diameter, approximately 300 000 cells per well). Cells
were transfected for 2 h, washed with Hank’s-buffered salt solution
(Life Technologies) to remove the transfection mixture, and further
incubated for 6 h.
Assessment of CAT-ELISA Cell lysis was performed 6 h after
transfection. Cells were washed with phosphate-buffered saline and
lyzed with 300 mL of Reporter Lysis Buffer (Promega) according to
the manufacturers’ instructions. Lysates were assayed for CAT
protein and overall protein concentration (BCA Protein assay, Pierce,
Rockford, Illinois). Two hundred microlitres of lysate was used
to quantitate CAT using the CAT ELISA Kit (Roche Molecular
Biochemicals, Mannheim, Germany) according to the manufacturers’
instructions. Measured CAT quantity was normalized to the overall
protein concentration in order to exclude the fact that results were
influenced by intersample variations in cell growth or cell number.
Statistics The results are expressed as mean  SD. Statistical
differences were determined by the ANOVA test (Fisher’s protected
least significant difference).
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